Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients

References

• World Health OrganizationGuidelines for the prevention, care and treatment of persons with chronic hepatitis B infectionGeneva, SwitzerlandWHO2015 Available from: http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/Accessed June 29, 2015
   Google Scholar
• Chinese Society of Hepatology and Chinese Society of Infectious Disease, Chinese Medical Association[The guideline of prevention and treatment for chronic hepatitis B] (2010 version)Chin J Epidemiol2011324405415 Chinese
   Google Scholar
• ChenCJYangHIIloejeUHHepatitis B virus DNA levels and outcomes in chronic hepatitis BHepatology2009495 SupplS72S8419399801
   PubMed Web of Science ®Google Scholar
• LiawYFKaoJHPriatvisuthTAsian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatol Int2008226328319669255
   PubMed Web of Science ®Google Scholar
• LokASMcMahonBJChronic hepatitis B: update 2009Hepatology200950366166219714720
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the LiverEASL clinical practice guidelines: management of chronic hepatitis B virus infectionJ Hepatol201257116718522436845
   PubMed Web of Science ®Google Scholar
• YaoGBZhuMCuiZYWangBEYaoJLZengMDA 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in ChinaJ Dig Dis200910213113719426396
   PubMed Web of Science ®Google Scholar
• ZengMDMaoYMYaoGBFive years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis BLiver Int201232113714622097972
   PubMed Web of Science ®Google Scholar
• HouJLYinYKXuDZTelbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trialHepatology200847244745418080339
   PubMed Web of Science ®Google Scholar
• JiaJDHouJLYinYKTwo-year results of a phase III comparative trial of telbivudine vs lamivudine in Chinese patientsHepatology200746Suppl 1189
   Google Scholar
• ZhuangHWengXHDevelopment and management of drug resistance to nucleoside/nucleotide analogues in patients with chronic hepatitis BChin J Hepatol2013211522
   Google Scholar
• TujiosSRLeeWMUpdate in the management of chronic hepatitis BCurr Opin Gastroenterol201329325025623519135
   PubMed Web of Science ®Google Scholar
• ChenEQWangLCLeiJXuLTangHMeta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virusVirol J2009616319818142
   PubMed Web of Science ®Google Scholar
• WangMYuanLQiaoBLiYTwo rescue therapies in lamivudine-resistant patients with chronic hepatitis B in the central China: adefovir monotherapy and adefovir plus lamivudineVirus Genes2014481323724203098
   PubMed Web of Science ®Google Scholar
• HaMZhangGDiaoSRescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapyIntern Med201251121509151522728482
   PubMed Web of Science ®Google Scholar
• PattersonSJAngusPWPost-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analoguesCurr Opin Organ Transplant200914322523019373086
   PubMed Web of Science ®Google Scholar
• LiuFWangXWeiFEfficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysisVirol J2014115924673792
   PubMed Web of Science ®Google Scholar
• YuJHShiJPWuJEfficacy and safety of lamivudine plus adefovir combination therapy and entecavir monotherapy for chronic hepatitis B patientsChin J Hepatol2011198892
   PubMedGoogle Scholar
• MaXJChenXPChenXFEfficacy of lamivudine and adefovir de novo combination therapy or after monotherapy in chronic hepatitis B patientsChin J Hepatol20122098102
   PubMedGoogle Scholar
• ZhangJCDe novo combination therapy with lamivudine and adefovir dipivoxil versus entecavir monotherapy naive chronic hepatitis B patients with high viral loadsChin J Clin Infect Dis20125142144
   Google Scholar
• RenNYanJCaiHDWuLThe observation of 96-weeks efficacy of lamivudine plus adefovir combination initial therapy for HBeAg-positive chronic hepatitis BInt J Virol201219113117
   Google Scholar
• YanJChenCRZhuYJEfficacy and economic analysis of lamivudine plus adefovir dipivoxil de-novo and optimize combination therapy of 144 weeks for chronic hepatitis B patientsInt J Epidemiol Infect Dis2013403842
   Google Scholar
• WangJShiJPZhuMFChenGYLiuJZhouXThe efficacy and safety comparison between nucleoside (acid) analogue initial combination and monotherapy in the treatment of chronic hepatitis B for 144 weeksChin J Exp Clin Virol2014288284
   Google Scholar
• WangLCChenEQCaoJDe novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patientsHepatol Int2011567167621484140
   PubMed Web of Science ®Google Scholar
• Expert committee of combination treatment for chronic hepatitisBExpert consensus of combination treatment for chronic hepatitis BChin J Hepatol201243946
   Google Scholar
• National Bureau of Statistics of China Available from: http://data.stats.gov.cn/easyquery.htm?cn=C01Accessed June 29, 2015
   Google Scholar
• WuBLiTChenHFShenJFCost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysisValue Health201013559260020561341
   PubMed Web of Science ®Google Scholar
• HeJBowenJMXieFGoereeRCost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in CanadaValue Health201215689490622999140
   PubMed Web of Science ®Google Scholar
• Mommeja-MarinHMondouEBlumMRRousseauFSerum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literatureHepatology2003371309131912774009
   PubMed Web of Science ®Google Scholar
• ButiMBrosaMCasadoMARuedaMEstebanRModeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis BJ Hepatol20095164064619576651
   PubMed Web of Science ®Google Scholar
• ChenLA cost-effectiveness study on Avarbose to treat type 2 diabetes. China Master’s Theses Full-Text Database 2008 Available from: http://d.wanfangdata.com.cn/Thesis/D446438Accessed June 29, 2015
   Google Scholar
• The team of pharmacoeconomic evaluations. [China Guidelines for Pharmacoeconomic Evaluations]Chin J Pharm Econ20105543 Chinese
   Google Scholar
• The prices of Chinese Medicine Available from: http://www.zgyyjgw.com/front/cn/retailPriceAccessed June 29, 2015
   Google Scholar
• LevyARKowdleyKVIloejeUThe impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected personsValue Health200811352753818179664
   PubMed Web of Science ®Google Scholar
• ClaxtonKSculpherMMcCabeCProbabilistic sensitivity analysis for NICE technology assessment: not an optional extraHealth Econ200514433934715736142
   PubMed Web of Science ®Google Scholar
• LavanchyDHepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measuresJ Viral Hepat2004119710714996343
   PubMed Web of Science ®Google Scholar
• KowdleyKVThe cost of managing chronic hepatitis B infection a global perspectiveJ Clin Gastroenterol200438132133
   Web of Science ®Google Scholar
• ZhangYLianJQLiYTelbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudineEur J Gastroenterol Hepatol20132581481923406845
   PubMed Web of Science ®Google Scholar
• LeeYBLeeJHChoiWMEfficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infectionAntimicrob Agents Chemother2013576325633224100506
   PubMed Web of Science ®Google Scholar
• JayakumarRJoshiYKSinghSLaboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovirJ Lab Physicians20124101622923916
   PubMedGoogle Scholar
• SungJJLaiJYZeuzemSLamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis BJ Hepatol20084872873518329126
   PubMed Web of Science ®Google Scholar
• VeenstraDLSullivanSDClarkeLCost-effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis BPharmacoeconomics20072596397717960954
   PubMed Web of Science ®Google Scholar
• WuGCZhouWPZhaoYRStudy on the natural history of chronic hepatitis BChin J Hepatol2002104648
   PubMedGoogle Scholar
• HuangHZhuCWYuXFWangGSWangJYThe development of cirrhosis in Chinese patients with chronic hepatitis BHepatol Int20076437440
   Google Scholar
• XuBHuDCRosenbergDMChronic hepatitis B: a long-term retrospective cohort study of disease progression in ShanghaiChin J Gastroenterol Hepatol2003181213451352
   Google Scholar
• ChenYCChuCMYehCTLiawYFNatural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up studyHepatol Int20071126727319669348
   PubMed Web of Science ®Google Scholar
• HuiAYChanHLLeungNWHungCChanFKSungJJSurvival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensationJ Clin Gastroenterol200234556957211960072
   PubMed Web of Science ®Google Scholar
• WangSBWangJHChenJGiriRKChenMHNatural history of liver cirrhosis in south China based on a large cohort study in one center: a follow-up study for up to 5 years in 920 patientsChin Med J2012125122157216222884146
   PubMed Web of Science ®Google Scholar
• LoCMFanSTLiuCLChanSCWongJThe role and limitation of living donor liver transplantation for hepatocellular carcinomaLiver Transpl200410344044715004774
   PubMed Web of Science ®Google Scholar
• WuTJChanKMChouHSLiver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma: the influence of viral characteristics on clinical outcomeAnn Surg Oncol201320113582359023760589
   PubMed Web of Science ®Google Scholar
• YaoGBRenHXuDZResults of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patientsChin J Hepatol20091712881886
   PubMedGoogle Scholar
• ChenEQZhouTYLiuLLiuCLeiMTangHA comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective studyHepat Mon2011111273122087113
   PubMed Web of Science ®Google Scholar
• YuenMFSetoWKFungJWongDKYuenJCLaiCLThree years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safetyAm J Gastroenterol20111061264127121364549
   PubMed Web of Science ®Google Scholar
• HouJLGaoZLXieQTenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trialJ Viral Hepat2015228391
   Web of Science ®Google Scholar
• LeeSHeathcoteEJSievertWTenofovir disoproxil fumarate (TDF) versus adefovir dipivoxil (ADV) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B participating in studies 102 and 103 [poster no. 980]Poster presented at: 59th Annual Meeting of the American Association for the Study of Liver DiseasesOctober 31–November 4, 2008San Francisco, CA
   Google Scholar
• Snow-LampartAChappellBCurtisMWeek 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg QD [poster no. 977]Poster presented at: 59th Annual Meeting of the American Association for the Study of Liver DiseasesOctober 31–November 4, 2008San Francisco, CA
   Google Scholar
• HuMChenWAssessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, ChinaValue Health200912Suppl 3S89S9220586991
   PubMedGoogle Scholar
• GaoQEconomic analysis for liver and renal transplant in a transplant centerChina Master’s Theses Full-Text Database 2007 Available from: http://d.wanfangdata.com.cn/Thesis/Y1326546Accessed June 29, 2015
   Google Scholar
• National Bureau of Statistics of China Available from: http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htmAccessed June 29, 2015
   Google Scholar
• YaoGBChenCWLuWLEfficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in ChinaHepatol Int2008213619669291
   PubMedGoogle Scholar